Abstract 169P
Background
Anti-PD1/PDL1 therapy has been established as standard care for first- and second-line treatment patients with advanced Non-Small Cell Lung Cancer (NSCLC), and tumor immune microenvironment (TIME) is elemental to predict how patients respond to immunotherapy and their prognosis. The multiplex immunohistochemistry (mIHC) provides the possibility to deeper characterize the infiltrating immune cells and classify patients more precisely.
Methods
FFPE tissues were collected from 231 NSCLC patients, and TIME tests were performed using a validated commercial mIHC assay. Images were analyzed using the APTIME software by 3D Medicines. Tumor parenchyma and stroma were differentiated by CK staining.
Results
In our study, patients with squamous cell carcinomas exhibited a higher stromal density of CD68+CD163+ M2 macrophage cells (p= 0.020), PD-L1+ cells (P= 0.029), compared to those with adenocarcinoma. While patients with adenocarcinoma showed a higher stromal density of CD3+CD4+ cells (P=0.046). There were no significant differences in immune cell infiltration between younger (age<=60) and older (age>60) groups. In addition to mIHC, 171 samples underwent next-generation sequencing (NGS). Among 103 patients with available tumor mutation burden (TMB) results, patients with TMB-H (≥10 muts/Mb) exhibited higher median density of stromal CD20+ B cells (P=0.009) and CD3+ T cells (p=0.004). Additionally, patients carrying EGFR mutations (n =159) had lower infiltration of T cells than those with wild-type EGFR (N=162), including tumoral CD3+ T cells (P<0.001), CD 8+T cells (P<0.001), PD-1+CD8+(P<0.001), as well as tumoral PD-1+ cells (p=0.006) and PD-L1+CD68+ cells (p=0.024). Patients carrying MET mutations (n =3) had a higher level of tumoral CD3+ T cells than those with wild-type (P<0.008). Patients carrying BRAF mutations (n=5) had a higher level of tumoral CD56bright NK cells than those with wild-type (n=166) (P=0.024). There were no significant differences observed between KRAS mutant (n=20) and wild-type (n=151) groups.
Conclusions
Together, these data outlined the immune infiltration associations with clinical and molecular features in NSCLC. Tumor immune microenvironment might serve as a promising biomarker for immunotherapy.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
102P - Dynamic profiling of ctDNA in HER2-alterated advanced NSCLC treated with pyrotinib and apatinib: Exploratory biomarker analysis from a phase II trial
Presenter: Yucheng Dong
Session: Poster session 08
103P - Epigenetic regulated genes enhanced fragmentomics-based model for early-stage lung cancer detection
Presenter: Yadong Wang
Session: Poster session 08
104P - The development of a classifier of somatic copy number alteration burden in liquid biopsy with potential clinical impact in advanced non-small cell lung cancer (NSCLC)
Presenter: Laura Bonanno
Session: Poster session 08
105P - Plasma ctDNA dynamics as clinical response biomarker for NSCLC: A systematic review and meta-analysis
Presenter: Luís Leite
Session: Poster session 08
106P - Longitudinal molecular characterization in plasma of EGFR mutant non-small cell lung cancer (NSCLC) experiencing early progression (EPD) on first-line osimertinib (Osi)
Presenter: Laura Bonanno
Session: Poster session 08
107P - Germline pathogenic variants identified in tissue- and blood-based whole exome sequencing in advanced solid tumors
Presenter: Takeshi Kuwata
Session: Poster session 08
108P - Assessing molecular characteristics in a large cohort of anal squamous cell carcinoma patients
Presenter: Cristina Smolenschi
Session: Poster session 08
109P - Development and validation of a digital PCR assay for detection and monitoring of universally methylated circulating tumor DNA in patients with high-grade sarcoma
Presenter: Elisabeth Ashton
Session: Poster session 08
110P - 13-plex non-invasive genotyping in HPV related cancers in the MOSCATO trial
Presenter: Elise Rupp
Session: Poster session 08
111P - Leveraging circulating tumor DNA sequencing for first-line cancer treatment: Insights from two prospective precision medicine studies
Presenter: Veronique Debien
Session: Poster session 08